Jonas Salk's Polio Vaccine Journey: 5 Major Obstacles Overcome

Salk's path to the inactivated polio vaccine (IPV, 1955) faced:

  1. Funding scarcity – relied on NFIP (March of Dimes) grants; limited lab space.
  2. Scientific skepticism – killed-virus approach doubted; live-attenuated (Sabin) favored by many.
  3. Viral complexity – 3 serotypes; needed formalin inactivation preserving immunogenicity.
  4. Safety rigor – massive field trial (1.8M children); Cutter incident (live virus in batches) → stricter regulation.
  5. Public pressure – polio panic demanded speed; Salk resisted premature release.

IPV eliminated wild polio in Americas by 1994; global eradication near.

Reflexology - Related Articles